Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST)

EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

The interim analysis showed no recurrence of cancer in approximately 97% of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83% of those who underwent surgery but received a placebo. The investigators made these results public because the study had met its primary endpoint in terms of rate of recurrence-free survival.

The study involving more than 600 patients was sponsored by the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH). It was conducted at multiple cancer centers in the US and Canada, and was led by the of Surgeons Oncology Group. Novartis supplied Gleevec for use in the study, and also provided partial funding under a Cooperative Research and Development Agreement with NCI to support the clinical development of Gleevec.

Gleevec has already been confirmed as an effective therapy in its approved use for patients with advanced metastatic or unresectable (inoperable) Kit- positive GIST. In a statement issued today by the NIH, the new findings were heralded as excellent news, with major implications for patients with primary disease.

"With these new data, we see that Gleevec may help patients with early GIST," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "We will now work with the investig
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:11/26/2014)... , Nov. 26, 2014  Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... two upcoming investor conferences. On Tuesday, December ... Annual Piper Jaffray Healthcare Conference.  D. Keith ... an update on the company beginning at 11:30 a.m., ...
(Date:11/26/2014)... -- Cohen, Placitella & Roth, PC is investigating potential ... Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 2011 through November 2, 2014 ("Class Period").  The ... officers and directors publically disseminated materially false and/or ... 20(a) of the Securities Exchange Act of 1934 ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Avanir ... that the U.S. Food and Drug Administration (FDA) ... New Drug Application (NDA) for AVP-825. AVP-825 is ... sumatriptan powder delivered intranasally utilizing a novel Breath ... Complete Response letter, and consistent with the preliminary ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
... 15, 2011 PDI, Inc. (Nasdaq: ... promotional outsource services to established and emerging health care ... partnership with Qforma, the leading provider of advanced analytics ... Through this agreement, PDI will gain access ...
... REDWOOD CITY, Calif., March 15, 2011 – Ingenuity® ... solutions for life science researchers, today announced new ... in IPA®. Processed RNA-Seq datasets can now be ... context of pathways and diseases for a rich ...
Cached Medicine Technology:PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 2Ingenuity Announces RNA-Sequencing Workflow Support and First-of-Its-Kind microRNA Filtering Capability With Latest Release of IPA 3
(Date:11/27/2014)... (PRWEB) November 27, 2014 "As a ... embarrassing side effects of urinary incontinence," said an inventor ... and developed this specialized accessory to prevent leakage and ... Incontinence to absorb urine leakage. This prevents stains on ... potential embarrassment. The pad ensures that the individual has ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 Tylenol ... who were allegedly injured by the medication are continuing ... federal litigation is looking ahead to a status conference ... to a Scheduling Order issued earlier this year, a ... December 16th at 10:00 a.m. Items likely to be ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut Pro ... FCPX to the next level. , “ProPip allows users to ... of a mouse,” said Christina Austin, CEO of Pixel Film ... appreciate.” , With ProPip users can show off their ... ProPip is great for commentaries, news casting, and more. PROPIP™ ...
(Date:11/27/2014)... to help with chores while they are home from school, ... self-esteem, and above all, helps parents maintain a somewhat tidy ... do you encourage your children to want to help? Is ... Development Journal, there is. The study found that adults’ language ... lend a hand. , The study found that using ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3
... Centers and free coffee ... give blood, DETROIT, Jan. 8 In honor of ... Cross Donors,Employees and Volunteers in Michigan for two weeks in ... all donors,at any of the participating American Red Cross blood ...
... among 19 countries when it comes to deaths that could ... care, according to new research supported by The Commonwealth Fund ... other nations dramatically improved these rates between 199798 and 200203, ... performed as well as the top three countries out of ...
... States places last among 19 countries when it comes ... to timely and effective health care, according to new ... the January/February issue of Health Affairs. While other nations ... U.S. improved only slightly. , If the U.S. had ...
... government intent on promoting innovation and fuelled by the ... abroad, Chinas health biotech industry only needs a more ... in the production of therapies and medicines both ... new study. , Long considered a skillful product replicator, ...
... for seniors underscore need for Congress to allow price,negotiation, ... 75 percent of Medicare drug plans continue to hike ... of $369 for five,commonly used drugs, between the month ... tracked increased prices on the five drugs by more ...
... NATICK, Mass., Jan. 7 Boston Scientific,Corporation (NYSE: ... for the,Federal Circuit affirmed a District Court ruling which ... patent owned by Johnson & Johnson.,The Appeals Court also ... invalid and affirmed the infringement of that claim. The ...
Cached Medicine News:Health News:Dunkin' Donuts Celebrates the New Year by Supplying Goodies to Michigan's American Red Cross 2Health News:New study: US ranks last among other industrialized nations on preventable deaths 2Health News:US ranks last among other industrialized nations on preventable deaths 2Health News:China's biotech industry: An Asian dragon is growing 2Health News:China's biotech industry: An Asian dragon is growing 3Health News:China's biotech industry: An Asian dragon is growing 4Health News:China's biotech industry: An Asian dragon is growing 5Health News:China's biotech industry: An Asian dragon is growing 6Health News:China's biotech industry: An Asian dragon is growing 7Health News:Most Medicare Drug Plans Continue to Hike Costs into 2008 Two-to-Three Times Rate of Inflation 2Health News:Most Medicare Drug Plans Continue to Hike Costs into 2008 Two-to-Three Times Rate of Inflation 3Health News:Boston Scientific Announces Court Decision 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
Medicine Products: